Takara Bio Inc. (TYO:4974)

Market Cap	104.40B
Revenue (ttm)	43.05B
Net Income (ttm)	-52.00M
Shares Out	120.42M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	41.61
Dividend	17.00 (1.93%)
Ex-Dividend Date	Mar 28, 2025

Volume	565,100
Average Volume	481,375
Open	885.00
Previous Close	882.00
Day's Range	861.00 - 894.00
52-Week Range	861.00 - 1,186.00
Beta	0.24
RSI	23.48
Earnings Date	Feb 13, 2025

About Takara Bio

Takara Bio Inc., together with its subsidiaries, engages in bioindustry, contract development and manufacturing organization (CDMO), and gene therapy businesses in Japan, China, rest of Asia, the United States, Europe, and internationally. The company sells reagents and instruments, including genetic research reagents and testing kits; products related to coronavirus testing comprising in vitro diagnostics that detect viruses; analytical reagents; single-cell analysis systems; gene expression research reagents; fluorescent proteins series; geno...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 1,838
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4974

Financial Performance

In 2023, Takara Bio's revenue was 43.51 billion, a decrease of -44.33% compared to the previous year's 78.14 billion. Earnings were 1.48 billion, a decrease of -90.76%.